Drugs / KSL-W
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01877421 | Feb 2014 → Aug 2015 | gingivitis | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSL-W | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01877421 ↗ |
| Modality | Peptide | “Novel Antimicrobial Peptide KSL-W Anti-Plaque Chewing Gum.” PMID 39466933 ↗ Dec 2024 |
| Route | Oral | “This study is to assess the safety and tolerability of single doses and multiple doses in reducing plaque and gingivitis when delivered in a chewing gum formulation.” NCT01877421 ↗ |